Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 2/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9027044 | 1.00 | TSHR (0.44) | TSHRGABRA1GABRB1UGT2B7GRN | |
| SCHEMBL11898232 | 1.00 | TSHR (0.44) | TSHRGABRA1GABRB1UGT2B7GRN | |
| SCHEMBL19667846 | 0.94 | GABRA1 (0.42) | TSHRGABRA1GABRB1UGT2B7GRN | |
| SCHEMBL17025386 | 0.85 | GABRA1 (0.37) | TSHRGABRA1GABRB1UGT2B7EPAS1 | |
| SCHEMBL17025364 | 0.85 | GABRA1 (0.37) | TSHRGABRA1GABRB1UGT2B7EPAS1 | |
| SCHEMBL1834420 | 0.84 | EPAS1 (0.43) | GABRA1GABRB1UGT2B7GRNSORT1 | |
| SCHEMBL1835863 | 0.84 | EPAS1 (0.43) | GABRA1GABRB1UGT2B7GRNSORT1 | |
| SCHEMBL27860515 | 0.80 | ALDH1A1 (0.39) | GABRA1GABRB1UGT2B7CYP3A4CNR2 | |
| SCHEMBL31401464 | 0.79 | TPMT (0.59) | TSHRGRNSORT1TPMTADRB2 | |
| SCHEMBL630804 | 0.79 | PDE2A (0.47) | GRNSORT1CNR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961231-B2 | NTCP inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-03-30 | — | — | US | disclosed |
| US-20210040072-A1 | NTCP Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-02-11 | — | — | US | disclosed |
| CN-112218878-A | NTCP inhibitors | 北京生命科学研究所 | 2021-01-12 | — | — | CN | disclosed |
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2968280-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| WO-2014153037-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153037-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040072-A1 | NTCP Inhibitors | HAVCR2, NPC1, HMGCR | TSHR 2808/4885GABRA1 3077/4885GABRB1 3366/4885 |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | P2RX3, P2RX1, P2RX4 | TSHR 354/4885GABRA1 3387/4885GABRB1 3557/4885 |
| US-10961231-B2 | NTCP inhibitors | HAVCR2, NPC1, HMGCR | TSHR 2808/4885GABRA1 3077/4885GABRB1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.